Melt-in-Mouth migraine pill could make dosing easier
NCT ID NCT07680686
First seen Jul 02, 2026 · Last updated Jul 02, 2026
Summary
This study tests a new orally disintegrating tablet (ODT) of ubrogepant, a migraine medication, to see how it is absorbed compared to the standard immediate-release tablet. Healthy adult volunteers take the drug under fasting and fed conditions to measure levels in the blood and check for side effects. The goal is to find out if the ODT version works similarly and could offer a more convenient option for people who have trouble swallowing pills.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
ubrogepant
What this could lead to
If successful, this could lead to a more convenient, easier-to-take version of ubrogepant for migraine relief.
What could go wrong
This is an early-phase study in healthy volunteers, not migraine patients. The new tablet may not work as well or could cause unexpected side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEALTHY VOLUNTEER are added.
By submitting, you agree to our Terms of use
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Adimanebart Bioavailability Study in Healthy Adu NCT07673601
- BIIB144 First-in-Human Safety Study (NCT07662148)
- Nacresertib-Itraconazole Interaction Study | NCT07649954
- SIF001 Epilepsy Trial Safety Study NCT07051629
- ABBV-722 First-in-Human Safety Study (NCT06673238)
- Inhaled TRL1068 Safety Study in Healthy Voluntee NCT07644195
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••